David A. Siegel Arcellx, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Arcellx, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 48,400 shares of ACLX stock, worth $2.67 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
48,400
Previous 7,800
520.51%
Holding current value
$2.67 Million
Previous $432,000
679.17%
% of portfolio
0.01%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ACLX
# of Institutions
186Shares Held
43.4MCall Options Held
73.8KPut Options Held
196K-
Perceptive Advisors LLC New York, NY3.93MShares$217 Million5.74% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.82MShares$211 Million9.96% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$207 Million18.28% of portfolio
-
Black Rock Inc. New York, NY3.07MShares$169 Million0.01% of portfolio
-
Sr One Capital Management, LP2.35MShares$130 Million54.95% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.42B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...